



August 27-29, 2024 | Boston, MA

Exclusive Speaker Interview

Bruce Morimoto

Vice President, Drug Development

Alto Neuroscience



How have you seen the field of digital measures evolve over time?

In recent years, the development of digital measures has moved beyond pure data collection to include mapping of the data to clinical outcomes. This mechanistic correlation will be key to the future use of digital measures for drug approval.

What do you think the key milestones have been for the industry with respect to digital measures?

Many digital measures are being incorporated into observation and longitudinal clinical studies. This historical data when analysed in the context of a clinically meaningful benefit will further the use of these measures in early clinical research.

What current developments are you most excited about?

Traditional assessments have often been collected at discrete clinic visits. These visits represent a very small fraction of the patient's experience in a clinical trial. It is important capture and analyse data in the patient's natural environment. Digital measures have the potential to fill this void.

What do you see as being the key challenges for us to turn these developments into realities?

There are many platforms, technologies and algorithms for the collection and analysis of digital data. Key to success is data sharing and harmonization of the data sets. This can be done in a pre-competitive nature which will benefit all. The challenge is to bring together the various stakeholders to agree on the format and content of sharing.

And finally, why are you excited for the 3rd Digital Biomarkers & Clinical Measures for Neurology Summit?

The 3rd Digital Biomarkers & Clinical Measures for Neurology Summit will bring together many stakeholders to facilitate networking and discussions about the current best practices and future needs of this developing area.

[View The Agenda](#)

